#### UNIVERSITY OF PITTSBURGH SCHOOL OF NURSING

# ADMINISTRATIVE POLICIES AFFECTING THE SCHOOL OF NURSING

TITLE OF POLICY: FACULTY RESEARCH PROPOSAL REVIEWS

**DATE EFFECTIVE:** February 11, 2014

LAST REVIEWED/REVISED: May 27, 2014

**POLICY:** All faculty research proposals planned for submission to any funding agency (internal or external) must receive both external scientific review and budget approval. Proposals that do not follow this policy are at risk of not being accepted by the University upon award. The purpose of this policy is to ensure the quality of research proposals submitted by faculty researchers from the School of Nursing. For external scientific review outside the University, the Office of Research Submission Form for the Evaluation of Research Confidentiality /Non-Disclosure Agreement (CDA/NDA) must be completed.

#### **PROCEDURE:**

Core elements of procedures for submitting grants are presented below.

- 1. The Principal Investigator (PI) meets with the department Vice Chair for Research (VCR) preferably at least 2-3 months prior to the SON Office of Grants Management submission deadline to discuss the proposal, departmental processes of submission, required documents, and development of the budget. The Grant Submission Timeline is given to the PI and reviewed with particular attention to the information needed to begin development of the budget. The department grants analyst is notified of the planned submission. If the application is for an educational training grant (HRSA, ACIE), the Associate Dean for Clinical Education is notified. Policy 408B should be followed.
- 2. The PI schedules an appointment with the department grants analyst to meet and discuss the submission process and begin development of the budget.
- 3. The PI and VCR will meet throughout the submission process.
- 4. The PI and VCR discuss the review process and the PI is responsible for identifying at least two external reviewers who are approved by the VCR. Once the PI emails the proposal to the VCR, the proposal and SON Scientific Review Form is emailed to reviewers who are asked to complete and return the review form and comments to the PI and VCR within an agreed upon timeframe.
- 5. The VCR will discuss reviews with the PI and will
  - a. If minor or no revisions are suggested by reviewers: provide scientific approval or
  - b. If major revisions are suggested by a reviewer: Inform the PI that the application may require substantial revision and re-review.
- 6. The department chair where the PI resides is responsible for providing written final approval of the budget and budget justification.
- 7. Grants analysts should be 1) notified in writing that scientific and budget approval have been granted, and 2) receive final proposal documents from the PI at least 10 business days prior to the funding agency deadline. Proposals that do not meet this deadline are at risk of not being submitted by the funding agency deadline.
- 8. For external scientific review outside the University, the Office Of Research Submission Form for the Evaluation of Research Confidentiality /Non-Disclosure Agreement (CDA/NDA) must be completed.

Reference: Policy 408B - Guidelines For Submitting Educational Proposals

Attachments: Review Form, Proposal Acceptability Form, Research Confidentiality /Non-Disclosure Agreement

Approved by Administration: 05/08, 02/14

Reviewed: 01/97, 03/99, 12/01; 03/04, 04/08, 02/14 Revised by Administration: 04/04; 11/04, 05/08, 02/14

#### SCHOOL OF NURSING SCIENTIFIC REVIEW FORM

have a conflict of inter		ne proposal objectively, plea	are confidential. If you feel you se inform the department Vice				
Please check her	e if you wish to remair	n anonymous					
Application Title							
Principal Investigator (s)							
Funding AgencyAward Mechanism (if pertinent)							
Date Sent to Reviewer_							
Impact	Score	Strengths	Weaknesses				
·	1. Exceptional	Exceptionally strong	Essentially no weaknesses				
High Impact	2. Outstanding	Extremely strong	Negligible weaknesses				
	3. Excellent	Very strong	Only some minor weaknesses				
Moderate Impact	4. Very Good	Strong	Numerous minor weaknesses				
	5. Good	Strong	At least one moderate weakness				
	6. Satisfactory	Some strengths	Some moderate weaknesses				
	7. Fair	Some strengths	At least one major weakness				
Low Impact	8. Marginal	A few strengths	A few major weaknesses				
	9. Poor	Very few strengths	Numerous major weaknesses				

**Overall Impact**: Provide an overall impact score to reflect your assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the five core review criteria and the additional review criteria. Please pay particular attention to the specific aims and ensure that they mesh with the proposed work.

Core Review Significance		ia (cir 2	cle) 3	4	5	6	7	8	9			
Investigators	1	2	3	4	5	6	7	8	9			
Innovation	1	2	3	4	5	6	7	8	9			
Approach	1	2	3	4	5	6	7	8	9			
Environment	1	•	_									
	•	2	3	4	5	6	7	8	9			
Additional Re Statistical Ana	eview				2		-		9	7	8	9
	eview alyses	Criter		cle)			-			7	8	9

Overall Impact Score (circle) 1

(circle) Acceptable as is 
Acceptable with minor revisions 
Needs substantial revision and re-review

Please return review form and comments via email to department Vice Chair of Research and the PI

### SCHOOL OF NURSING PROPOSAL ACCEPTABILITY FORM

Proposal Number:			
PI:			
Title:			
This proposal has been reviewed by:	V	N	
Reviewer 1:	Yes	No	
Reviewer 2:			
Department Vice Chair for Research:			
This proposal is acceptable for submission:			
This proposal is not acceptable for submission at this time			
Department Vice Chair for Research	Date		
Department Chair	Date		
Reviewers: Name, University, School or Department			
Reviewer 1:			
Reviewer 2			

## UNIVERSITY OF PITTSBURGH OFFICE OF RESEARCH (OR) SUBMISSION FORM FOR THE EVALUATION OF

#### RESEARCH CONFIDENTIALITY /NON-DISCLOSURE AGREEMENTS (CDA/NDA)

FOR UNIVERSITY REVIEW AND SIGNATURE, SUBMIT THE FOLLOWING MATERIALS BY EMAIL (CLINCORP@PITT.EDU) OR FAX (412/624-7414):

\*\*\*COMPLETED SUBMISSION FORM AND THE CDA ISSUED BY THE COMPANY/INSTITUTION (F AVAILABLE).

University Principal Investigator (PI) Contact Information:	Company/Institution name providing or receiving information:
Name:	
Title:	
Email:  3. PI's Departmental Administrative Contact for CDA/NDA Follow-up:	A Commonwill notify than Logal Contact for any changes to CDB/NIDB:
(Not Office of Research Staff)	Company/Institution Legal Contact for any changes to CDA/NDA:     Name:
Name:	Email/Phone:
Phone/Email:	Emain-mone.
Pl's Department: Pl's Dept. ID:	
5. Are there any other parties to the CDA/NDA who are not under your	6. Company/Institution PI name:
supervision? No Yes Ifyes, list all that apply:	o, company/mattation i i name.
☐ Indicate here if Company/Institution does not have a	FOR CDAS FOR CLINICAL TRIALS:
preferred form of CDA and desires Pitt to generate the CDA.	15. Is the specific purpose of this CDA/NDA to discuss a
General:	clinical trial agreement/protocol?
<ol><li>Is this CDA/NDA to permit discussions solely regarding</li></ol>	No- please skip the rest of this column
commercial licensing activity with the other party?	Yes Please check all that apply below.
□No	
Yes- Please direct your request to the Office of Technology	☐ The study is investigator initiated. This means a Pitt faculty
Management (OTM)	member has had substantive intellectual input into the
	protocol design; <b>OR</b>
8. Is this CDA/NDA related to your potential private consulting	
activity with the other party?	☐ The trial is industry designed and sponsored but the
□ No	experimental drug or device being evaluated in the trial:
Yes- The Office of Research cannot review this CDA/NDA.	~ emits ionizing radiation; and/or
You should review any consulting arrangement with your Chair.	~ involves a gene transfer intervention; and/ or
Tod should review any consulting arrangement with your chair.	~ involves a transgenic xenotransplant; OR
9. Pitt requires a specific purpose for each research CDA. What	involves a dansgeme xeriod ansprant, ore
is the overall purpose of this CDA/NDA?	☐ The study involves no use whatsoever of UPMC space,
13 the overall parpose of this CDANDA!	patients or records; <b>OR</b>
	patients of records, OR
10 M/hat information is the ather party disclosing to your	The Di bas a Diff regular faculty appointment but lacks a
10. What information is the other party disclosing to you:	☐ The PI has a Pitt regular faculty appointment but lacks a UPMC/UPP appointment; <b>OR</b>
11. What non-public information are you disclosing to the other	OPMOOPP appointment, OR
party?	
party	☐ The study is being financially supported by industry
	but has been designed by a collaborator at another non-
40.16:	profit institution.
12. If you are disclosing non-public information, did you develop	
this information or do you have the full rights to disclose this	
information:	■ None of the above apply to this trial. Please contact:
No, please explain:	the UPMC OSPARS OFFICE 412-647-4461 for
☐Yes	instructions on submission.
13. If you are disclosing non-public information, is it related to a	OSPARS handles confidentiality agreements for the
potentially patentable invention or discovery?	review of industry-designed protocols to determine
□No	UPMC's interest in participating in the clinical trial.
Yes, Office of Technology Management staff name:	OSPARS also negotiates the clinical trial agreements for
	industry-designed and funded protocols most often
14. If this relates to any other agreement, please list all that	involving an industry-held Investigational New Drug (IND)
apply, i.e., Sponsored Research Agreement, Government or	application or Investigational Device Exemption (IDE) for the
Other Grant, CDA, License, MTA, Other Agreement	material being evaluated in the clinical trial.
To the best of my knowledge, the answers to the questions are true,	complete and accurate. I have read the referenced agreement and
agree to comply with its terms and conditions. I am a University of F	
information noted above.	ranga oranga karanga karanga 🛣 di dalam karanga karanga karanga di Karanga karanga karanga karanga karanga di Karanga kar
Principal Investigator:	Date:

Please note that a faculty and staff are not permitted to sign a University CDA or NDA as the sole endorsing signature, and that any such signature is not binding on the University of Pittsburgh unless an appropriately Authorized University Official, i.e. Director of the Office of Research or his designee, also signs.